Method and composition for treating and preventing mycobacterium infections

A method of preventing or treating a mycobacterium infection comprising administering to a mammal an effective amount of at least one compound of the formula I:

• 15
• wherein
• R1 is H, halogen, hydroxyl, amino, C1-6 alkyl, aryl-C1-6 alkyl, mono-or poly- fluorinated C1-6 alkyl, hydroxy-C1-6 alkyl, C1-6 alkoxy, amino-C1-8 alkyl, C1-6 alkylamino, di(C1-6 alkyl)amino, C1-8 alkylamino-C1-8 alkyl, di(C1-6 alkyl) amino C1-8 alkyl, cyclohexyl, aryl, or heterocycle, wherein aryl or heterocycle may each be unsubstituted or substituted with one or more of the following:
• C1-6 alkyl, C1-6 alkoxy, hydroxy-C1-4 alkyl, hydroxyl, amino, C1-6 alkylamino, di(C1-6 alkyl) amino, amino-C1-8 alkyl, C1-8 alkylamino-C1-8 alkyl, di(C1-6 alkyl)amino-C1-8 alkyl, nitro, azido or halogen;
• R2 is H, halogen, hydroxyl, C1-6 alkyl, aryl-C1-6 alkyl, mono- or poly- fluorinated C1-6 alkyl, aryl or heterocycle;
• R3 and R4 are independently selected from the group consisting of H, halogen, hydroxyl, amino, C1-6 alkyl, aryl-C1-6 alkyl, mono- or poly- fluorinated C1-6 alkyl, hydroxy-C1-6 alkyl, amino-C1-8 alkyl, C1-8 alkylamino-C1-8 alkyl, di(C1-6 alkyl)amino-C1-8 alkyl, cyclohexyl, aryl or heterocycle;
• and R3 and R4 can be taken together to form a 5-7 membered saturated cycle ring or heterocyclic ring;
• R5 and R6 are independently selected from the group consisting of H, C1-6 alkyl, aryl-C1-6 alkyl, mono- or poly-fluorinated C1-6 alkyl, aryl or heterocycle;
• and R5 and R6 can be taken together to form a 5-7 membered saturated cycle ring or heterocycle ring;
• R7 is H, halogen, methyl, or ethyl;
• R8 and R9 are independently selected from the group consisting of H, halogen, C1-6 alkyl, aryl-C1-6 alkyl, mono- or poly- fluorinated C1-6 alkyl, hydroxy-C1-6 alkyl, amino-C1-8 alkyl, C1-8 alkylamino-C1-8 alkyl, di(C1-6 alkyl)amino-C1-8 alkyl, cyclohexyl, aryl or heterocycle;
• and R8 and R9 can be taken together to form a 5-7 membered saturated cycle ring or heterocyclic ring;
• R10 is halogen, O, OR11, NOR11, NHOR11, NOR12, NHOR12, NR11R12, NR12, or NR12R13;
• wherein R11 is H, acyl, P(O)(OH)2, S(O)(OH)2, CO(C1-10 alkyl)CO2H, (C1-8 alkyI)CO2H, CO(C1-10 alkyl)NR12R13, (C1-8 alkyl) NR12R13;
• R12 and R13 are independently selected from the group consisting of H, C1-6 alkyl, aryl, and aryl-C1-6 alkyl;
• and R12 and R13 can be taken together to form a 5-7 membered saturated heterocyclic ring containing said nitrogen;
• or a pharmaceutically acceptable salt thereof.